Still, broad uptake has long been an uphill battle for the gene therapy as it competes with a variety of treatments including, Roche’s blockbuster Hemlibra, Sanofi’s newer sales driver Altuviiio and ...

Twenty years ago, our son declared bankruptcy. As the years passed, he improved his credit rating. Recently, he lost his job and maxed out his credit cards. He now lives with us and doesn’t own a ...

SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to ...

When recent Tulane University grad Ishaan Pomichter was taking a digital technology class taught by famed biographer and writer Walter Isaacson last year, the young tech devotee decided to curate a ...

BURLEY, Idaho, Jan. 20, 2026 /PRNewswire/ -- Redox Bio-Nutrients, LLC today announced that its biostimulant product Mainstay® Si received a top certification from The Fertilizer Institute (TFI), ...

Led by Bessemer Venture Partners, the highly oversubscribed round comes 18 months after founding, following strong commercial traction and scientific results Despite the momentum, there's still a ...

BELLAIRE, Texas (AP) — BELLAIRE, Texas (AP) — Bio-Path Holdings Inc. (BPTH) on Tuesday reported a loss of $976,000 in its third quarter. The Bellaire, Texas-based company said it had a loss of 11 ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Medical biotechnology company ...

Instil Bio, Inc. (NASDAQ: TIL) stock is trading lower on Tuesday. Axion Bio Inc., a wholly-owned subsidiary of Instil, decided to discontinue clinical development of AXN-2510. AXN-2510, Instil’s lead ...

Venture capital firm Aditum Bio is going all-out for a new collaboration with Fosun Pharma, launching a subsidiary with the sole purpose of developing novel therapies in tandem with the Shanghai-based ...

Nuvation Bio is downgraded from Buy to Hold as its stock price now reflects improved Ibtrozi rollout visibility and strong fundamentals. Ibtrozi's commercial launch is robust, with early patient ...